Pre-tax profits at the Irish unit of French pharmaceutical company Servier fell 11% to €54.97m even as revenues jumped.

Pre-tax profits at the Irish unit of French pharma giant, Servier last year dipped by 2.7% to €61.8m in spite of a jump in revenues.

Restructuring charges of €1.3m at the main Irish unit of French pharma giant, Servier last year contributed to pre-tax profits declining by 4% to €63.55m.

Pre-tax profits at the main Irish unit of pharmaceutical giant Servier increased 37% last year to €66.2m as revenues topped €600m.

Pre-tax profits at the main Irish unit of French pharma giant, Servier, last year more than doubled to €48.4 million as revenues topped €550m.

Pre-tax profits at the main Irish unit of French pharma giant Servier last year decreased by 23% to €23.4m in spite of a sharp increase in revenues.

AN Irish-made medicine has been shown to reduce death and hospitalisation due to heart failure by more than a quarter in a worldwide study.

One hundred jobs are being created today in Co Wicklow

AN Irish-made drug used to lower the heart rate in people with heart disease can help reduce the risk of heart attack by more than 40%, according to new research.

IRISH consumers are paying 20% more than they should for medicines because pharmaceutical companies are doing deals to prevent cheaper medicines coming on the market.

HEART rate, often overlooked in assessing patients, is a significant risk factor for heart disease, a groundbreaking study reveals, prompting calls by professionals for it to be routinely checked.

A study has found that a medicine produced in Ireland could bring new hope to people suffering from type 2 diabetes.

THOUSANDS of diabetes sufferers could be saved by an Irish-made medicine which has come through worldwide trials with flying colours.

Investment in research and development is to exceed €1.5bn for the first time, it was revealed today.

A new €7.5m health research project could potentially cut heart disease and stroke here by half.

Government spending on science and research programmes is to reach almost €230m this year, it was announced today.